aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japa...
January 14 2021 - 8:00AM
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel biological pathways, today announced that its partner Kyorin
Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of
Kyorin Holdings, Inc., has completed the last subject visit in its
Phase 1 clinical trial of aTyr’s lead therapeutic candidate
ATYR1923 (known as KRP-R120 in Japan). This achievement has
triggered a milestone payment to aTyr.
“We applaud Kyorin for its timely advancement of
this study. We are highly encouraged by their progress with the
clinical program for ATYR1923 in Japan since becoming our partner
early last year,” said Dr. Sanjay Shukla, M.D., M.S., President and
Chief Executive Officer of aTyr.
The Phase 1 trial, which is being conducted by
Kyorin, is a placebo-controlled study to evaluate the safety,
pharmacokinetics and immunogenicity of ATYR1923 in 32 healthy
Japanese male volunteers. Results from this study are intended to
enable Kyorin to initiate patient trials in interstitial lung
disease (ILD) in Japan.
Kyorin is aTyr’s partner for the development and
commercialization of ATYR1923 for ILDs in Japan.
About
ATYR1923
aTyr is developing ATYR1923 as a potential
therapeutic for patients with inflammatory lung diseases. ATYR1923,
a fusion protein comprised of the immuno-modulatory domain of
histidyl tRNA synthetase fused to the FC region of a human
antibody, is a selective modulator of neuropilin-2 that
downregulates the innate and adaptive immune response in
inflammatory disease states. aTyr recently completed enrollment in
a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in
patients with pulmonary sarcoidosis, a form of interstitial lung
disease. This Phase 1b/2a study is a multi-ascending dose,
placebo-controlled, first-in-patient study of ATYR1923 that has
been designed to evaluate the safety, tolerability, steroid sparing
effect, immunogenicity and pharmacokinetics profile of multiple
doses of ATYR1923. In response to the COVID-19 pandemic, aTyr
completed a Phase 2 clinical trial with ATYR1923 in COVID-19
patients with severe respiratory complications. This Phase 2 study
was a randomized, double blind, placebo-controlled study that was
designed to evaluate the safety and preliminary efficacy of a
single dose of ATYR1923.
About aTyr
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
biological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit
http://www.atyrpharma.com.About
Kyorin
Trusted among patients and professionals in the
medical industry, Kyorin Pharmaceutical Co., Ltd. strives to be a
company that contributes to public health and is recognized as one
with social significance by improving its presence in specific
therapeutic areas and through global discovery of novel drugs.
Kyorin Pharmaceutical Co., Ltd. uses a franchise customer strategy
where its marketing efforts are focused on respiratory,
otolaryngology and urology. In drug discovery, it is deploying
'selection and concentration' and promoting activities aimed at
first-in-class drug discovery, such as actively searching for and
introducing external drug discovery themes as well as multi-tiered
program development. For more information, please visit
http://www.kyorin-pharm.co.jp. Forward-Looking
Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are usually
identified by the use of words such as “anticipates,” “believes,”
“estimates,” “expects,” “intends,” “may,” “plans,” “projects,”
“seeks,” “should,” “will,” and variations of such words or similar
expressions. We intend these forward-looking statements to be
covered by such safe harbor provisions for forward-looking
statements and are making this statement for purposes of complying
with those safe harbor provisions. These forward-looking statements
include statements regarding the potential therapeutic benefits and
applications of ATYR1923; timelines and plans with respect to
certain development activities (such as the scope and timelines of
clinical trials), potential benefits of collaborations and certain
development goals. These forward-looking statements also reflect
our current views about our plans, intentions, expectations,
strategies and prospects, which are based on the information
currently available to us and on assumptions we have made. Although
we believe that our plans, intentions, expectations, strategies and
prospects, as reflected in or suggested by these forward-looking
statements, are reasonable, we can give no assurance that the
plans, intentions, expectations or strategies will be attained or
achieved. All forward-looking statements are based on estimates and
assumptions by our management that, although we believe to be
reasonable, are inherently uncertain. Furthermore, actual results
may differ materially from those described in these forward-looking
statements and will be affected by a variety of risks and factors
that are beyond our control including, without limitation,
uncertainty regarding the COVID-19 pandemic, risks associated with
the discovery, development and regulation of our product
candidates, the risk that we or our partners may cease or delay
preclinical or clinical development activities for any of our
existing or future product candidates for a variety of reasons
(including difficulties or delays in patient enrollment in planned
clinical trials), the possibility that existing collaborations
could be terminated early, and the risk that we may not be able to
raise the additional funding required for our business and product
development plans, as well as those risks set forth in our most
recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q
and in our other SEC filings. Except as required by law, we assume
no obligation to update publicly any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact: |
|
Ashlee Dunston |
|
Director, Investor Relations and
Corporate Communications |
|
adunston@atyrpharma.com |
|
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
aTyr Pharma (NASDAQ:LIFE)
Historical Stock Chart
From Apr 2023 to Apr 2024